Cardiac electrophysiologists have many options for treating arrhythmias, including catheter ablation and implantable cardiac defibrillators. Antiarrhythmic agents, which are pharmaceutical agents used to suppress fast rhythms of the heart (cardiac arrhythmias), represent another treatment option. This issue summarizes the most current thinking on the role of pharmaceuticals in relation to other types of treatment, helping electrophysiologists to determine the best method for managing their patients.
By Peter R. Kowey, MD and Gerald V. Naccarelli, MD
Elsevier is a leading publisher of health science books and journals, helping to advance medicine by delivering superior education, reference information and decision support tools to doctors, nurses, health practitioners and students. With titles available across a variety of media—print, online and handheld, we are able to supply the information you need in the most convenient format.